ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "certolizumab pegol"

  • Abstract Number: L09 • 2019 ACR/ARP Annual Meeting

    A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial

    Merete Lund Hetland1, Espen A Haavardsholm 2, Anna Rudin 3, Dan Nordström 4, Mike Nurmohamed 5, Bjorn Gudbjornsson 6, Jon Lampa 7, Kim Hørslev-Petersen 8, Till Uhlig 9, Gerdur Grondal 10, Mikkel Østergaard 11, Marte Heiberg 2, Jos Twisk 12, Kristina Lend 7, Simon Krabbe 13, Joakim Lindqvist 7, Anna-Karin Ekwall 14, Kathrine Lederballe Grøn 15, Meliha Kapetanovic 16, Francesca Faustini 7, Riitta Tuompo 17, Tove Lorenzen 18, Giovanni Cagnotto 19, Eva Baecklund 20, Oliver Hendricks 21, Daisy Vedder 22, Tuulikki Sokka-isler 23, Tomas Husmark 24, Maud-Kristine Aga Ljoså 25, Eli Brodin 26, Torkell Ellingsen 27, Annika Söderbergh 28, Milad Rizk 29, Åsa Reckner 30, Line Uhrenholt 31, Per Larsson 32, Soeren Just 33, David Stevens 34, Trine Laurberg 35, Gunnstein Bakland 36, Inge Christoffer Olsen 37, Ronald van Vollenhoven 38 and The NORD-STAR Study Group 39, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, 4Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 5Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, 6Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 7Karolinska Institutet, Stockholm, Sweden, 8Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, 9Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 10Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, 11Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 12Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, 13Rigshospitalet, København, Denmark, 14University of Gothenburg, Kullavik, Sweden, 15Rigshospitalt Glostrup, Glostrup, Denmark, 16Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, 17Helsinki University Hospital, Helsinki, Finland, 18Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, 19Lund University, Malmö, Sweden, 20Uppsala University, Uppsala, Sweden, 21Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 22Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, 23Jyvaskyla Central Hospital, Jyvaskyla, Finland, 24Rheumatology Clinic, Falun, Sweden, 25Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 26Haukeland University Hospital, Bergen, Norway, 27Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 28Örebro University Hospital, Ôrebro, Sweden, 29Västmanlands Hospital, Västerås, Sweden, 30Rheumatology Department, Linkoping, Sweden, 31Aalborg Universitetshospital, Aalborg, Denmark, 32Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 33Odense University Hospital, Odense, 34St. Olav's University Hospital, Trondheim, Norway, 35Aarhus University Hospital, Aarhus, Denmark, 36University Hospital of North Norway, Tromsø, Norway, 37Oslo University Hospital, Oslo, Norway, 38Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, 39Site investigators in all participating countries, Stockholm, Sweden

    Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
  • Abstract Number: 1506 • 2019 ACR/ARP Annual Meeting

    Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results

    Xenofon Baraliakos1, Sebastian Kruse 2, Simone Auteri 3, Natasha de Peyrecave 4, Tommi Nurminen 5, Thomas Kumke 5, Bengt Hoepken 6 and Jürgen Braun 2, 1Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 2Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, 3UCB Pharma, Brussels, Belgium, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Monheim, Germany, 6UCB Pharma, Monheim am Rhein, Germany

    Background/Purpose: Inflammation of the spine is believed to trigger a repair mechanism that results in syndesmophyte formation in axial spondyloarthritis (axSpA) patients (pts).1 Bone marrow…
  • Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting

    Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis

    Atul Deodhar1, Lianne Gensler 2, Jonathan Kay 3, Walter P. Maksymowych 4, Nigil Haroon 5, Robert B.M. Landewé 6, Martin Rudwaleit 7, Stephen Hall 8, Lars Bauer 9, Bengt Hoepken 9, Natasha de Peyrecave 10, Thomas Kumke 11 and Désirée van der Heijde 12, 1Oregon Health & Science University, Portland, OR, 2University San Francisco California, San Francisco, CA, 3UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 4University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, 5Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, 6Amsterdam University Medical Center, Amsterdam, Netherlands, 7Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, 8Monash University and Emeritus Research, Melbourne, Australia, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Slough, United Kingdom, 11UCB Pharma, Monheim, Germany, 12Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…
  • Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting

    Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol

    Laura Coates1, Joseph Merola 2, Arthur Kavanaugh 3, Philip Mease 4, Owen Davies 5, Oscar Irvin-Sellers 6, Tommi Nurminen 7 and Désirée van der Heijde 8, 1University of Oxford, Oxford, United Kingdom, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3University of California, San Diego School of Medicine, La Jolla, CA, 4Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 5UCB Pharma, Slough, England, United Kingdom, 6UCB Pharma, Slough, UK, Slough, United Kingdom, 7UCB Pharma, Monheim, Germany, 8Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
  • Abstract Number: 2068 • 2019 ACR/ARP Annual Meeting

    Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications

    Vivian Bykerk1, Andrew Blauvelt 2, Jeffrey Curtis 3, Cécile Gaujoux-Viala 4, Tore K. Kvien 5, William J. Sandborn 6, Kevin Winthrop 7, Christina Popova 8 and Xavier Mariette 9, 1Hospital for Special Surgery, New York City, NY, 2Oregon Medical Research Center, Portland, OR, USA, Portland, OR, 3University of Alabama at Birmingham, Birmingham, AL, 4Nîmes University Hospital, Nîmes, France, 5Diakonhjemmet Hospital, Oslo, Norway, 6University of California, La Jolla, CA, 7Oregon Health and Science University, Portland, OR, 8UCB Pharma, Brussels, Belgium, 9Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France

    Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).…
  • Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting

    The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol

    Ruediger Mueller1, Michael Spaeth2, Cord von Restorff3, Christoph Ackermann4 and Johannes von Kempis5, 1Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, 2Division of Rheumatology, Spital Linth, Uznach, Switzerland, 3Private rheumatologic practice, Männedorf, Switzerland, 4Private rheumatologic practice, Triesen, Liechtenstein, 5Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
  • Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting

    Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study

    Naohiro Sugitani1,2, Eiichi Tanaka1, Eisuke Inoue1,3, Eri Sugano1, Kumiko Saka1, Moeko Ochiai1, Rei Yamaguchi1, Yoko Shimizu1, Naoki Sugimoto1, Katsunori Ikari1, Ayako Nakajima1,2, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 3Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
  • Abstract Number: 622 • 2018 ACR/ARHP Annual Meeting

    DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study

    Janet E. Pope1, Emmanouil Rampakakis2, Julie Vaillancourt2, Eric Grant3, Louis Bessette4, Juris Lazovskis5, Boulos Haraoui6 and John S. Sampalis7, 1Department of Medicine, University of Western Ontario, London, ON, Canada, 2JSS Medical Research, Montreal, QC, Canada, 3Private Practice, Saint John, NB, Canada, 4Laval University, Québec, QC, Canada, 5Riverside Professional Centre, Sydney, NS, Canada, 6Institut de Rhumatologie de Montreal, Montreal, QC, Canada, 7McGill University, Montreal, QC, Canada

    Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either…
  • Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)

    Atul A. Deodhar1, Lianne S. Gensler2, Jonathan Kay3, Walter P. Maksymowych4, Nigil Haroon5, Robert B.M. Landewé6, Martin Rudwaleit7, Stephen Hall8, Lars Bauer9, Bengt Hoepken9, Natasha de Peyrecave10, Brian Kilgallen11 and Désirée van der Heijde12, 1Oregon Health and Science University, Portland, OR, 2University of California San Francisco, San Francisco, CA, 3Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, 4Department of Medicine, University of Alberta, Edmonton, AB, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 7Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, 8Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, 9UCB Pharma, Monheim, Germany, 10UCB Pharma, Brussels, Belgium, 11UCB Pharma, Raleigh, NC, 12Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
  • Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting

    Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series

    Marianna Meroni1, Maria De Santis2, Elena Generali2, Angela Ceribelli3, Marta Caprioli3, Giacomo Maria Guidelli2, Natasa Isailovic2, Gaetano Maria Fara4, Carlo Selmi2 and Maurizio Cutolo5, 1Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, 2Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 3Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, 4Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy

    Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…
  • Abstract Number: 2516 • 2018 ACR/ARHP Annual Meeting

    Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol

    Alain Saraux1, René-Marc Flipo2, Francis Fagnani3, Gabrielle Cukierman4, Isabelle Bru4, Jean-Michel Joubert4, Jan-Christof Schuller5, Jacques Massol6 and Bernard Combe7, 1CHU La Cavale Blanche, Brest, France, 2Hôpital Roger Salengro, Lille, France, 3Cemka-Eval, Bourg-la-Reine, France, 4UCB Pharma, Colombes, France, 5UCB Pharma, Brussels, Belgium, 6CHU de Besançon, Besançon, France, 7CHU Lapeyronie, Montpellier, France

    Background/Purpose: The safety and efficacy of certolizumab pegol (CZP) for treating patients (pts) with rheumatoid arthritis (RA) are well-established in a clinical trial setting.1,2 However,…
  • Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting

    Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis

    Johanna Gehin1, Silje Watterdal Syversen2, Guro Løvik Goll2, David J Warren1, Joseph Sexton3, Eldri Kvein Strand4, Tore Kvien3,5,6, Elisabeth Lie2,6 and Nils Bolstad7, 1Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Lillehammer Revmatismesykehus, Lillehammer, Norway, 5NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, 6On behalf of the NOR-DMARD registry, Oslo, Norway, 7Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway

    Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…
  • Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting

    Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis

    Yesim Ozguler1, Sinem Nihal Esatoglu1, Guzin Karatemiz1, Ali Ugur Unal2, Gul Guzelant1, Elif Dincses3, Mustafa Erdogan1, Sema Kaymaz Tahra2 and Gulen Hatemi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey

     Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
  • Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting

    Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis

    Joseph Tkacz1, Edward Lee2, Robert Low2, Jeffrey Stark2, Mohamed Yassine2 and Brenna Brady1, 1Health Analytics LLC, Columbia, MD, 2UCB Pharma, Smyrna, GA

    Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
  • Abstract Number: 1309 • 2017 ACR/ARHP Annual Meeting

    Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

    Megan E. B. Clowse1, Angela E. Scheuerle2, Christina D Chambers3, Anita Afzali4, Alexa Kimball5, John J. Cush6, Maureen Cooney7, Laura Shaughnessy7, Mark Vanderkelen8 and Frauke Förger9, 1Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 2UT Southwestern Medical Center, Dallas, TX, 3UC San Diego School of Medicine, San Diego, CA, 4University of Washington Harborview Medical Center, Seattle, WA, 5Beth Israel Deaconess Medical Center, Boston, MA, 6Baylor Scott & White Research Institute, Dallas, TX, 7UCB Pharma, Raleigh, NC, 8UCB Pharma, Braine-l’Alleud, Belgium, 9Inselspital, University of Bern, Bern, Switzerland

    Background/Purpose: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently,…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology